【AI Explained】Neurological updates: neurological complications of CAR-T therapy.

Literature Information

TL;DR

This paper discusses the neurological toxicity associated with chimeric antigen receptor (CAR)-T cell therapy, specifically focusing on immune effector cell-associated neurotoxicity syndrome (ICANS), which affects over 50% of patients and can require intensive care despite being typically self-limiting. It emphasizes the importance for neurologists to recognize the clinical manifestations, mechanisms, and treatment approaches for CAR-T-related neurotoxicity as these therapies become more widely used in treating B cell malignancies and other tumors.

Search for more papers on MaltSci.com

Adverse events · Chimeric antigen receptor T cell (CAR-T) · Neurological · Side-effects

Abstract

Chimeric antigen receptor (CAR)-expressing T cells now offer an effective treatment option for people with previously refractory B cell malignancies and are under development for a wide range of other tumours. However, neurological toxicity is a common complication of CAR-T cell therapy, seen in over 50% of recipients in some cohorts. Since 2018, the term immune effector cell-associated neurotoxicity syndrome (ICANS) has been used to describe and grade neurotoxicity seen after CAR-T cells and other similar therapies. ICANS following CAR-T therapy is usually self-limiting but can necessitate admission to the intensive care unit and is rarely fatal. As CAR-T therapies enter routine clinical practice, it is important for neurologists to be aware of the nature of neurological complications. Here, we summarise the clinical manifestations, mechanisms, investigations and recommended treatment of CAR-T-related neurotoxicity, focusing on the licensed CD19 products.

MaltSci.com AI Research Service

Primary Questions Addressed

1. What are the specific clinical manifestations of ICANS in patients undergoing CAR-T therapy?
2. How do the mechanisms of neurotoxicity in CAR-T therapy differ from those seen in other immunotherapies?
3. What are the current best practices for monitoring and managing neurological complications in CAR-T therapy patients?
4. How does the incidence of neurological complications vary between different CAR-T products, particularly the licensed CD19 therapies?
5. What are the long-term neurological outcomes for patients who experience ICANS following CAR-T therapy?

Key Findings

Research Background and Objective

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a significant advancement in treating refractory B cell malignancies. However, neurological complications associated with this therapy, specifically immune effector cell-associated neurotoxicity syndrome (ICANS), occur in over 50% of recipients. This paper aims to summarize the clinical manifestations, mechanisms, investigations, and treatment recommendations for CAR-T-related neurotoxicity, focusing on the licensed CD19 CAR-T products.

Main Methods/Materials/Experimental Design

The study employs a comprehensive review of existing literature and clinical trials to delineate the characteristics of CAR-T therapy and its neurological complications. Key aspects include:

• Research Design: This is a narrative review that synthesizes findings from various clinical trials and observational studies related to CAR-T therapy.
• Inclusion and Exclusion Criteria: Studies were included based on their relevance to CAR-T therapy and neurological toxicity, excluding those not focusing on CD19-targeted therapies.
• Data Collection: Clinical features, grading systems, and management strategies were extracted from peer-reviewed articles and clinical guidelines.

The process can be visualized in the following flowchart:

• Primary and Secondary Endpoints: The primary endpoint was the identification of neurological complications post-CAR-T therapy, while secondary endpoints included treatment efficacy and long-term outcomes.

Key Results and Findings

1. Clinical Manifestations: Neurotoxicity presents with a variety of symptoms, including tremors, language difficulties, disorientation, and severe cases may lead to encephalopathy or seizures.
2. Timing: Symptoms typically onset 4-6 days post-infusion, peaking around days 7-9, with a resolution time of 3-8 weeks for most cases.
3. Grading of Neurotoxicity: The ICANS grading system, which categorizes neurotoxicity into grades 1-4 based on clinical presentation, is crucial for monitoring and management.
4. Incidence and Risk Factors: Reported incidence of neurotoxicity ranges from 21% to 64%, with severe cases occurring in 5% to 50% of patients. Higher tumor burden, CAR-T cell dose, and certain pre-existing conditions are significant risk factors.

Main Conclusion/Significance/Innovation

The study concludes that while CAR-T therapies, particularly anti-CD19 products, are effective for treating refractory B cell malignancies, they are frequently associated with significant neurological toxicities. The awareness and management of ICANS are critical for improving patient outcomes. This review highlights the need for standardized monitoring protocols and the potential for novel therapeutic interventions targeting the mechanisms of neurotoxicity.

Research Limitations and Future Directions

The review acknowledges several limitations:

• Data Scarcity: Long-term follow-up data on neurological outcomes post-CAR-T therapy are limited.
• Variability in Reporting: Differences in grading systems and definitions across studies can lead to inconsistent reporting of neurotoxicity.

Future research should focus on:

• Mechanistic Studies: Further investigation into the pathophysiology of ICANS and the development of targeted therapies.
• Long-term Outcomes: Establishing standardized follow-up protocols to assess the long-term neurological effects of CAR-T therapy.
• Preventative Strategies: Evaluating the efficacy of prophylactic treatments to mitigate the risk of neurotoxicity in high-risk populations.

References

1. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. - Frederick L Locke;Armin Ghobadi;Caron A Jacobson;David B Miklos;Lazaros J Lekakis;Olalekan O Oluwole;Yi Lin;Ira Braunschweig;Brian T Hill;John M Timmerman;Abhinav Deol;Patrick M Reagan;Patrick Stiff;Ian W Flinn;Umar Farooq;Andre Goy;Peter A McSweeney;Javier Munoz;Tanya Siddiqi;Julio C Chavez;Alex F Herrera;Nancy L Bartlett;Jeffrey S Wiezorek;Lynn Navale;Allen Xue;Yizhou Jiang;Adrian Bot;John M Rossi;Jenny J Kim;William Y Go;Sattva S Neelapu - The Lancet. Oncology (2019)
2. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. - Sattva S Neelapu;Frederick L Locke;Nancy L Bartlett;Lazaros J Lekakis;David B Miklos;Caron A Jacobson;Ira Braunschweig;Olalekan O Oluwole;Tanya Siddiqi;Yi Lin;John M Timmerman;Patrick J Stiff;Jonathan W Friedberg;Ian W Flinn;Andre Goy;Brian T Hill;Mitchell R Smith;Abhinav Deol;Umar Farooq;Peter McSweeney;Javier Munoz;Irit Avivi;Januario E Castro;Jason R Westin;Julio C Chavez;Armin Ghobadi;Krishna V Komanduri;Ronald Levy;Eric D Jacobsen;Thomas E Witzig;Patrick Reagan;Adrian Bot;John Rossi;Lynn Navale;Yizhou Jiang;Jeff Aycock;Meg Elias;David Chang;Jeff Wiezorek;William Y Go - The New England journal of medicine (2017)
3. Chimeric antigen receptor T cells for acute lymphoblastic leukemia. - Noelle V Frey - American journal of hematology (2019)
4. CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. - Candida Vitale;Paolo Strati - Frontiers in oncology (2020)
5. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. - Daniel W Lee;Bianca D Santomasso;Frederick L Locke;Armin Ghobadi;Cameron J Turtle;Jennifer N Brudno;Marcela V Maus;Jae H Park;Elena Mead;Steven Pavletic;William Y Go;Lamis Eldjerou;Rebecca A Gardner;Noelle Frey;Kevin J Curran;Karl Peggs;Marcelo Pasquini;John F DiPersio;Marcel R M van den Brink;Krishna V Komanduri;Stephan A Grupp;Sattva S Neelapu - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2019)
6. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. - Jennifer N Brudno;James N Kochenderfer - Blood reviews (2019)
7. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. - Daniel B Rubin;Husain H Danish;Ali Basil Ali;Karen Li;Sarah LaRose;Andrew D Monk;David J Cote;Lauren Spendley;Angela H Kim;Matthew S Robertson;Matthew Torre;Timothy R Smith;Saef Izzy;Caron A Jacobson;Jong Woo Lee;Henrikas Vaitkevicius - Brain : a journal of neurology (2019)
8. The superficial peroneal sensory nerve revisited. - J F Jabre - Archives of neurology (1981)
9. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. - Juliane Gust;Kevin A Hay;Laïla-Aïcha Hanafi;Daniel Li;David Myerson;Luis F Gonzalez-Cuyar;Cecilia Yeung;W Conrad Liles;Mark Wurfel;Jose A Lopez;Junmei Chen;Dominic Chung;Susanna Harju-Baker;Tahsin Özpolat;Kathleen R Fink;Stanley R Riddell;David G Maloney;Cameron J Turtle - Cancer discovery (2017)
10. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. - Sattva S Neelapu;Sudhakar Tummala;Partow Kebriaei;William Wierda;Cristina Gutierrez;Frederick L Locke;Krishna V Komanduri;Yi Lin;Nitin Jain;Naval Daver;Jason Westin;Alison M Gulbis;Monica E Loghin;John F de Groot;Sherry Adkins;Suzanne E Davis;Katayoun Rezvani;Patrick Hwu;Elizabeth J Shpall - Nature reviews. Clinical oncology (2018)

Literatures Citing This Work

1. Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy. - Victoria Smith Arnesen;Andrea Gras Navarro;Martha Chekenya - Cancers (2021)
2. [Mechanism and prevention strategies of neurotoxicity in CAR-T treatment of B cell tumors]. - Q Zhang;Y Xiao - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2021)
3. Managing therapy-associated neurotoxicity in children with ALL. - Deepa Bhojwani;Ravi Bansal;Alan S Wayne - Hematology. American Society of Hematology. Education Program (2021)
4. In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy. - Tianqing Xin;Li Cheng;Chuchao Zhou;Yimeng Zhao;Zhenhua Hu;Xiaoyan Wu - Frontiers in oncology (2022)
5. Rehabilitation Needs for Patients Undergoing CAR T-Cell Therapy. - Obada Obaisi;Rhodora C Fontillas;Krina Patel;An Ngo-Huang - Current oncology reports (2022)
6. [Consensus of Chinese experts on the clinical management of chimeric antigen receptor T-cell-associated neurotoxicity (2022)]. - ; - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2022)
7. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. - Emmanuel Donnadieu;Maik Luu;Miriam Alb;Brigitte Anliker;Silvia Arcangeli;Chiara Bonini;Biagio De Angelis;Rashmi Choudhary;David Espie;Anne Galy;Cam Holland;Zoltán Ivics;Chahrazade Kantari-Mimoun;Marie Jose Kersten;Ulrike Köhl;Chantal Kuhn;Bruno Laugel;Franco Locatelli;Ibtissam Marchiq;Janet Markman;Marta Angiola Moresco;Emma Morris;Helene Negre;Concetta Quintarelli;Michael Rade;Kristin Reiche;Matthias Renner;Eliana Ruggiero;Carmen Sanges;Hans Stauss;Maria Themeli;Jan Van den Brulle;Michael Hudecek;Monica Casucci - Journal for immunotherapy of cancer (2022)
8. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment. - Tianning Gu;Kejia Hu;Xiaohui Si;Yongxian Hu;He Huang - WIREs mechanisms of disease (2022)
9. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. - Dong-Rui Wang;Xian-Lin Wu;Ying-Li Sun - Signal transduction and targeted therapy (2022)
10. Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy. - Flavia Linguanti;Elisabetta Maria Abenavoli;Valentina Berti;Egesta Lopci - Cancers (2022)

… (23 more literatures)

© 2025 MaltSci - We reshape scientific research with AI technology